Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Last Updated: February 7, 2023

Details for Patent: 7,067,522

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 7,067,522
Title:2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
Abstract:Pyrimidine derivatives of formula (I) wherein Q.sub.1, Q.sub.2, G and R.sup.1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
Inventor(s): Pease; Elizabeth Janet (Macclesfield, GB), Williams; Emma Jane (Macclesfield, GB), Bradbury; Robert Hugh (Macclesfield, GB), Pearson; Stuart Eric (Macclesfield, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/995,931
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,067,522

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,067,522

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0004887Mar 01, 2000

International Family Members for US Patent 7,067,522

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 472537 See Plans and Pricing
Australia 2001233979 See Plans and Pricing
Australia 3397901 See Plans and Pricing
Brazil 0108879 See Plans and Pricing
Brazil 122014024864 See Plans and Pricing
Canada 2398887 See Plans and Pricing
China 1220684 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.